Targeted Therapy Directed by Genetic Testing in Treating Patients With Locally Advanced or Advanced Solid Tumors, The ComboMATCH Screening Trial
This ComboMATCH patient screening trial is the gateway to a coordinated set of clinical
trials to study cancer treatment directed by genetic testing. Patients with solid tumors that
have spread to nearby tissue or lymph nodes (locally advanced) or have spread to oth...
Age: Birth - 66+
Gender: All
DevRobust Treatment for Mal de Débarquement Syndrome
Mal de Débarquement Syndrome (MdDS) is an under-recognized balance disorder, which is
manifested by persistent false sensations of oscillatory self-motion (rocking/swaying) and/or
pulling in a specific direction (gravitational pull). Patients with MdDS typically exp...
Age: 18 - 78 years
Gender: All
Testing the Use of Ado-Trastuzumab Emtansine Compared to the Usual Treatment (Chemotherapy With Docetaxel Plus Trastuzumab) for Recurrent, Metastatic, or Unresectable HER2-Positive Salivary Gland Cancer
This phase II trial tests whether ado-trastuzumab emtansine works to shrink tumors in
patients with HER2-positive salivary gland cancer that has come back (recurrent), spread to
other places in the body (metastatic), or cannot be removed by surgery (unresectable).
...
Age: 18 years - 66+
Gender: All
Environmental Factors and Thyroid Cancer
Thyroid cancer incidence has been steadily increasing and has nearly tripled since the 1970's
in the US and worldwide. Early detection of small, papillary thyroid cancers using high
quality diagnostic imaging explains only about 50% of this increased incidence, sugg...
Age: 18 years - 66+
Gender: All
A Study Evaluating the Efficacy and Safety of Adjuvant Atezolizumab or Placebo and Trastuzumab Emtansine for Participants With HER2-Positive Breast Cancer at High Risk of Recurrence Following Preoperative Therapy
This is a Phase III, two-arm, randomized, double-blind placebo-controlled study in
participants with HER2-positive primary breast cancer who have received preoperative
chemotherapy and HER2-directed therapy, including trastuzumab followed by surgery, with a
findin...
Age: 18 years - 66+
Gender: All
De-Escalation of Breast Radiation Trial for Hormone Sensitive, HER-2 Negative, Oncotype Recurrence Score Less Than or Equal to 18 Breast Cancer (DEBRA)
This Phase III Trial evaluates whether breast conservation surgery and endocrine therapy
results in a non-inferior rate of invasive or non-invasive ipsilateral breast tumor
recurrence (IBTR) compared to breast conservation with breast radiation and endocrine
thera...
Age: 50 - 70 years
Gender: All
Testing the Combination of ZEN003694 and Nivolumab With or Without Ipilimumab in Solid Tumors
This phase I/Ib trial is to find out the best dose, possible benefits and/or side effects of
BET bromodomain inhibitor ZEN-3694 (ZEN003694) when given in combination with nivolumab with
or without ipilimumab in treating patients with solid tumors. ZEN003694 may stop...
Age: 18 years - 66+
Gender: All
Testing What Happens When an Immunotherapy Drug (Pembrolizumab) is Given by Itself Compared to the Usual Treatment of Chemotherapy With Radiation After Surgery for Recurrent Head and Neck Squamous Cell Carcinoma
This phase II trial studies the effect of pembrolizumab alone compared to the usual approach
(chemotherapy [cisplatin and carboplatin] plus radiation therapy) after surgery in treating
patients with head and neck squamous cell carcinoma that has come back (recurrent...
Age: 18 - 79 years
Gender: All
International Spontaneous Coronary Artery Dissection (SCAD) "iSCAD" Registry
The aim of "iSCAD," the International Spontaneous Coronary Artery Dissection (SCAD) Registry,
is to serve as an internationally collaborative, multicenter registry coordinated by an
experienced and centralized coordinating center in an effort to increase the pace of...
Age: 18 years - 66+
Gender: All
Treating Prostate Cancer That Has Come Back After Surgery With Apalutamide and Targeted Radiation Based on PET Imaging
This phase III trial tests two questions by two separate comparisons of therapies. The first
question is whether enhanced therapy (apalutamide in combination with abiraterone +
prednisone) added to standard of care (prostate radiation therapy and short term androgen...
Age: 18 years - 66+
Gender: Male
Ultrasound-Based Renal Sympathetic Denervation as Adjunctive Upstream Therapy During Atrial Fibrillation Ablation
The purpose of the ULTRA-HFIB Pilot is to determine the role of adjunctive renal denervation
(RDN) in the prevention of Atrial Fibrillation (AF) recurrence in patients scheduled for an
AF ablation procedure. Patients will be randomized to either i) AF ablation (Cont...
Age: 18 years - 66+
Gender: All
Study to Assess the Efficacy, Safety, and Tolerability of Intravitreal Aflibercept Compared to Laser Photocoagulation in Patients With Retinopathy of Prematurity (BUTTERFLEYE)
The primary objective of the study is to assess the efficacy of aflibercept compared to laser in patients diagnosed with retinopathy of prematurity (ROP). The secondary objectives of the study are to assess the need for a second treatment modality, to assess the recurre...
Age: 18 - 50 years
Gender: All
Pembrolizumab (MK-3475) Versus Placebo Following Surgery and Radiation in Participants With Locally Advanced Cutaneous Squamous Cell Carcinoma (MK-3475-630/KEYNOTE-630)
This is a randomized, double-blind, study that compares pembrolizumab (MK-3475) with placebo
given as adjuvant therapy in participants with high-risk locally advanced cutaneous squamous
cell carcinoma (LA cSCC) that have undergone surgery with curative intent in com...
Age: 18 years - 66+
Gender: All
Testing the Combination of Olaparib and Durvalumab, Cediranib and Durvalumab, Olaparib and Capivasertib, and Cediranib Alone in Recurrent or Refractory Endometrial Cancer Following the Earlier Phase of the Study That Tested Olaparib and Cediranib in Comparison to Cediranib Alone, and Olaparib Alone
This phase II trial studies the effects of the combination of olaparib and durvalumab,
cediranib and durvalumab, olaparib and capivasertib, and cediranib alone in treating patients
with endometrial cancer that has come back (recurrent) or does not respond to treatme...
Age: 18 years - 66+
Gender: Female
Post-resection Treatment of Large Colon Polyps
Patients who have provided informed consented and are scheduled to undergo endoscopic mucosal
resection (EMR) of lesions 15mm and larger will be randomized to STSC (80 W, Effect 5) vs APC
(preferred settings) vs No Treatment of the perimeter of the EMR site.
Age: 25 years - 66+
Gender: All
Safety and Efficacy of Pembrolizumab Compared to Placebo in Resected High-risk Stage II Melanoma (MK-3475-716/KEYNOTE-716)
This 2-part study will evaluate the safety and efficacy of pembrolizumab (MK-3475) compared to placebo in participants with surgically resected high-risk Stage II melanoma. Participants in Part 1 will receive either pembrolizumab or placebo in a double-blind design for ...
Age: 12 years - 66+
Gender: All
Active Surveillance, Bleomycin, Etoposide, Carboplatin or Cisplatin in Treating Pediatric and Adult Patients With Germ Cell Tumors
This phase III trial studies how well active surveillance help doctors to monitor subjects
with low risk germ cell tumors for recurrence after their tumor is removed. When the germ
cell tumors has spread outside of the organ in which it developed, it is considered
...
Age: Birth - 66+
Gender: All
A Study of Atezolizumab as Adjuvant Therapy in Participants With Renal Cell Carcinoma (RCC) at High Risk of Developing Metastasis Following Nephrectomy
This is a Phase III, multicenter, randomized, placebo-controlled, double-blind study to evaluate the efficacy and safety of atezolizumab versus placebo in participants with RCC who are at high risk of disease recurrence following nephrectomy.
Age: 18 years - 66+
Gender: All